[HTML][HTML] The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the …
…, S Hasegawa, K Inai, K Kernstine, H Kindler… - Journal of Thoracic …, 2016 - Elsevier
This article proposes codes for the primary tumor categories of adenocarcinoma in situ (AIS)
and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in …
and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in …
[HTML][HTML] Malignant pleural mesothelioma
AS Tsao, I Wistuba, JA Roth… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Malignant pleural mesothelioma (MPM) is a deadly disease that occurs in 2,000 to 3,000
people each year in the United States. Although MPM is an extremely difficult disease to …
people each year in the United States. Although MPM is an extremely difficult disease to …
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design
Background Methodological limitations of prior studies have prevented progress in the
treatment of patients with borderline resectable pancreatic adenocarcinoma. Shortcomings …
treatment of patients with borderline resectable pancreatic adenocarcinoma. Shortcomings …
[HTML][HTML] The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung …
…, S Hasegawa, K Inai, K Kernstine, H Kindler… - Journal of Thoracic …, 2016 - Elsevier
Abstract The IASLC Staging and Prognostic Factors Committee has collected a new
database of 94,708 cases donated from 35 sources in 16 countries around the globe. This …
database of 94,708 cases donated from 35 sources in 16 countries around the globe. This …
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the …
A Marabelle, M Fakih, J Lopez, M Shah… - The Lancet …, 2020 - thelancet.com
Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of …
response to immune checkpoint blockade. We prospectively explored the association of …
[HTML][HTML] Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Background Patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup
of those with metastatic pancreatic cancer. The poly (adenosine diphosphate–ribose) …
of those with metastatic pancreatic cancer. The poly (adenosine diphosphate–ribose) …
The uniqueness of the child–father attachment relationship: Fathers' sensitive and challenging play as a pivotal variable in a 16‐year longitudinal study
…, E Fremmer‐Bombik, H Kindler… - Social …, 2002 - Wiley Online Library
This longitudinal study of forty‐four families explored fathers' as compared to mothers'
specific contribution to their children's attachment representation at ages 6, 10, and 16 …
specific contribution to their children's attachment representation at ages 6, 10, and 16 …
[HTML][HTML] Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and …
HL Kindler, D Niedzwiecki, D Hollis… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose The combination of gemcitabine plus bevacizumab produced a 21% response rate
and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic …
and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic …
Integrative molecular characterization of malignant pleural mesothelioma
…, HC Silveira, VW Rusch, RC Rintoul, H Pass, H Kindler… - Cancer discovery, 2018 - AACR
Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest
cavity. To expand our understanding of MPM, we conducted a comprehensive integrated …
cavity. To expand our understanding of MPM, we conducted a comprehensive integrated …
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the …
Purpose We evaluated the safety and efficacy of concurrent administration of two
monoclonal antibodies, cetuximab and bevacizumab, in patients with metastatic colorectal …
monoclonal antibodies, cetuximab and bevacizumab, in patients with metastatic colorectal …